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Rheumatoid Arthritis (RA) has been increasingly associated with perturbations to the
microbial communities that reside in and on the body (the microbiome), in both human
and animal studies. To date, such studies have mainly focused on the microbial
communities that inhabit the gut and oral cavity. Mounting evidence suggests that
microbial DNA can be detected in the blood circulation using a range of molecular
methods. This DNA may represent an untapped pool of biomarkers that have the
potential to report on changes to the microbiome of distant sites (e.g., example,
the gut and oral cavity). To this end, through amplification and sequencing of the
bacterial 16S rRNA variable region four, we evaluated the presence and identity of
microbial DNA in blood samples obtained from RA patients (both prior to and 3 months
following the instigation of treatment) in comparison to a small number of healthy
control subjects and samples obtained from patients with ankylosing spondylitis (AS)
and psoriatic arthritis (PA). Bacterial-derived DNA was identified in the majority of our
patient samples. Taxonomic classification revealed that the microbiome community in
RA was distinct from AS, PA, and the healthy state. Through analysis of paired patient
samples obtained prior to and 3 months following treatment (V0 vs. V3), we found
the microbiome to be modulated by treatment, and in many cases, this shift reduced
the distance between these samples and the healthy control samples, suggesting a
partial normalization following treatment in some patients. This effect was especially
evident in seronegative arthritis patients. Herein, we provide further evidence for the
existence of a blood microbiome in health and identify specific taxa modulated in disease
and following treatment. These blood-derived signatures may have significant utility as
disease biomarkers and suggest this area warrants further investigation.
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INTRODUCTION
An increasing body of evidence demonstrates that the composition of the microbiome, the genetic
material of all microorganisms (bacteria, fungi, viruses, and protozoa) that reside within and on our
body, differs in health and disease, and further, that this shift in composition from the healthy state,
termed “dysbiosis,” may occur in a disease specific manner (Tani et al., 1997; Vaahtovuo et al., 2008;
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Liu et al., 2013, 2016; Ebringer and Rashid, 2014; Costello et al.,
2015; Scher et al., 2015, 2016a,b; Zhang et al., 2015; McDonald
et al., 2016; Wen et al., 2017; du Teil Espina et al., 2018; Lopez-
Oliva et al., 2018; Zhao et al., 2018a,b). Many resident microbiota
are opportunistic pathogens and have the potential to induce
disease if there is a breach in host defense. Such breaches in
resistance enable specific microbiota members to overpopulate
their usual place of habitation or to colonize areas of the body
that they are usually unable to do so (Pflughoeft and Versalovic,
2012). Recent studies have further revealed that evidence of the
microbiome (generally at the nucleic acid level) is detectable
in the circulatory system and report that this is the result of
microorganisms (or parts thereof) moving from their usual place
of habitation such as the gut, oral cavity, respiratory tract, into
the blood; a process termed atopobiosis (Potgieter et al., 2015;
Whittle et al., 2018; Castillo et al., 2019).
It is almost universally accepted that the circulatory system
of healthy humans is sterile based upon our general inability
to detect proliferating microorganisms (Potgieter et al., 2015).
However, a number of studies report the presence of proliferating
organisms in the circulation of apparently healthy subjects
(Damgaard et al., 2015; Castillo et al., 2019; Whittle et al., 2019)
or the presence of microorganism-associated components such
as microbial nucleic acids (DNA and RNA) (Nikkari et al., 2001;
Gosiewski et al., 2017; Whittle et al., 2019). Further, culture-
positive bacteremia following tooth brushing and the use of
oral irrigation devices is well-appreciated (Berger et al., 1974;
Maharaj et al., 2012), suggesting that the transient presence
of organisms within the circulation is well-tolerated in the
healthy host. In addition, there are numerous investigations that
report the presence of bacterial 16S rRNA sequences in human
blood samples in various disease states (diabetes, cardiovascular
disease, atherosclerosis, and Kawasaki disease) (Amar et al.,
2011, 2013; Trøseid et al., 2014; Abe et al., 2015). For a
comprehensive review of these studies, please refer to work by
Castillo et al. (2019).
RHEUMATOID ARTHRITIS, ANKYLOSING
SPONDYLITIS, PSORIATIC ARTHRITIS,
AND DYSBIOSIS
Mounting evidence suggests that the composition and status
of the microbiota have a crucial role in the pathogenesis of
chronic autoimmune diseases. Indeed, many studies associate
the existence of an imbalanced microbial community inside
the human body (commonly in the gastrointestinal tract) with
the initiation and progression of these disorders (Vaahtovuo
et al., 2008; Costello et al., 2015; Scher et al., 2015, 2016a;
Zhang et al., 2015; Wen et al., 2017; Gilis et al., 2018;
Langan et al., 2018, 2019). Rheumatoid arthritis (RA) is an
autoimmune disorder characterized by chronic inflammation
of the synovial joints leading to significant pain, swelling,
and disability with increased morbidity and mortality. RA is
estimated to affect ∼1% of the world population (Gibofsky,
2012) while in the UK it was estimated to affect 0.67% of
the population in 2014 (Abhishek et al., 2017). Despite this,
the underlying etiology of RA is still poorly understood.
Ankylosing spondylitis and Psoriatic arthritis belong to a group
of inflammatory diseases known as the spondyloarthritides
(Au et al., 2017). Ankylosing spondylitis (AS) is a persistent
autoimmune condition distinguished by inflammation of the
peripheral joints, the axial skeleton, and ligaments (Wen et al.,
2017). Psoriatic arthritis (PA) is a persistent inflammatory joint
disorder typically observed in patients with psoriasis. Both
spondyloarthritides have been associated with changes in the gut
microbiome (Gilis et al., 2018).
A number of studies have investigated chronic inflammatory
disease-associated dysbiosis at various body sites using a range of
molecular and biochemical approaches. RA has been associated
with dysbiosis of the gastrointestinal tract (Taneja, 2014; Zhang
et al., 2015; Chen et al., 2016; Liu et al., 2016; Horta-Baas et al.,
2017; Wu et al., 2017; du Teil Espina et al., 2018; Picchianti-
Diamanti et al., 2018; Wang and Xu, 2019), oral cavity (Zhang
et al., 2015; Cheng et al., 2017; Beyer et al., 2018; Lopez-Oliva
et al., 2018; Mikuls et al., 2018), lung (Scher et al., 2016b), and
synovial fluid (Martinez-Martinez et al., 2009; Reichert et al.,
2013; Zhao et al., 2018b) across a range of studies. Moreover,
these studies have begun to associate RA, or stages thereof, with
the presence or absence of specific bacteria, suggesting that the
microbiome may afford a valuable source of novel biomarkers
and or novel targets for therapeutic modulation (Brusca et al.,
2014; Costello et al., 2015; Zhang et al., 2015; Cheng et al., 2017;
Horta-Baas et al., 2017; Jethwa and Abraham, 2017; Wen et al.,
2017). A number of studies have applied these methodologies to
the study of Ankylosing spondylitis (AS) and Psoriatic arthritis
(PA), two other chronic inflammatory diseases, and have to
date investigated the gastrointestinal, oral and skin microbiome
(Jethwa and Abraham, 2017; Langan et al., 2018; Lewis et al.,
2019). Taken as a whole, these studies suggest that RA, AS, and
PA may result in (or from) pan-microbiome dysbiosis affecting
multiple niches.
Various disease states are associated with blood microbiome
dysbiosis (Amar et al., 2013; Sato et al., 2014; Lelouvier et al.,
2016; Mangul et al., 2016; Ling et al., 2017), and these changes
are likely reflective of dysbiosis at a distant site(s) with well-
characterized resident microbial communities. We believe that
these nucleic acids have leached from classical microbiome
niches into the blood. These may represent novel biomarkers
for disease pathogenesis. Despite mounting evidence suggesting
a key role for dysbiosis in the initiation and development
of RA, no study to date has investigated whether such
translocation occurs in these highly prevalent disorders, and
further, whether such data are of diagnostic, prognostic, or
therapeutic value.
To this end, this preliminary study aimed to: (a) characterize
the circulating microbiome of patients with rheumatoid arthritis
(RA), ankylosing spondylitis (AS), and psoriatic arthritis (PA),
relative to a number of healthy control subjects, and (b) explore
specific microbiome signatures associated with RA, AS, and
PA diseases that may increase our understanding of disease
pathogenesis and or reveal a pool of candidate biomarkers for
further development.
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MATERIALS AND METHODS
Donor Population
This study investigated the presence of bacterial 16S rRNA in
the serum of 20 rheumatoid arthritis patients. Serum samples
were collected both prior to (RA V0), and 3 months following
(RA V3) the instigation of treatment with disease modifying
anti-rheumatoid drugs. Ethical approval was obtained (NREC
16/LO/0957, London Brent Research Ethics Committee, IRAS
Project ID 198240), and all patients provided written informed
consent. In addition to the RA patient cohort, blood component
samples from four ankylosing spondylitis (AS) patients, four
psoriatic arthritis (PA) patients, and four healthy control subjects
were procured to facilitate preliminary exploration of any
differences between the different disease states (Table 1). These
samples were obtained from Sera Laboratories Limited. All
samples were analyzed anonymously, and the authors obtained
ethical approval (Keele University ERP3) and written informed
consent to utilize the samples for the research reported herein. All
methods were performed in accordance with relevant guidelines
and regulations.
Microbiome Characterization
Amplification and sequencing of bacterial 16S rRNA variable
region 4 were used to characterize the bacterial community
members present in the samples. The bacterial 16S rRNA was
amplified by PCR utilizing the oligonucleotide primers listed
in Table 2. First round PCR utilizing primers 16SV4_F and
16SV4_R was carried out in reactions comprising 4 µl of each
serum, 10 µl Phusion blood PCR buffer, 0.4 µl (2U) Phusion
blood DNA polymerase, 1 µl of each primer of (10 uM) 16S
rRNA, and 3.6 µl of the nuclease-free water that had been
subjected to 15min UV-irradiation, in a final volume of 20
µl. A negative control reaction in which serum was replaced
with an equal volume of UV-irradiated nuclease-free water was
included in each experiment to confirm that none of all reagents
were contaminated by target DNA. A positive control reaction
(Escherichia coli genomic DNA as a template) was also prepared
to confirm successful PCR amplification in each experiment.
Cycling parameters comprised an initial denaturation step
performed at 98◦C for 5min followed by 33 cycles of:
denaturation (98◦C, 10 s), annealing (55◦C, 5 s), and extension
(72◦C, 15 s). A final elongation of 7min at 72◦C completed
the reaction. Following electrophoretic separation of 5 µl of
each resulting PCR product to confirm successful amplification,
the remainder (15 µl) was purified of excess primer and PCR
reagents using the QIAquick PCR Purification kit. A “kit control”
was run alongside this process and involved the purification of 15
µl of UV irradiated nuclease-free water, again to ensure the kit
used was free from contaminating target DNA.
In order to add sequencing adapters to facilitate MiSeq library
preparation, a second round of PCR amplification was conducted
in a total volume of 50 µl comprising 10 µl 5× Platinum Super-
Fi Buffer, 1 µl 10mM dNTP mixture, 0.5 µl Platinum Super-
Fi polymerase, 2.5 µl of each XT_tagged primer (16SV4_XT
F/R), 5 µl from the successful first round PCR reaction, and
38.5 µl of UV-irradiated nuclease free water. Cycling parameters
TABLE 1 | Patient population.
Patient ID Disease status RF/CCP
status
Therapy
RA 135 Rheumatoid Positive MTX monotherapy
RA 138 Rheumatoid Negative MTX/SSZ/HCQ
RA 109 Rheumatoid Negative MTX monotherapy
RA 140 Rheumatoid Negative MTX monotherapy
RA 150 Rheumatoid Negative MTX/SSZ/HCQ
RA 151 Rheumatoid Positive MTX
RA 145 Rheumatoid Positive MTX/SSZ/HCQ
RA 139 Rheumatoid Negative SSZ/HCQ
RA 146 Rheumatoid Positive MTX/HCQ
RA 111 Rheumatoid Negative MTX/HCQ
RA 141 Rheumatoid Positive MTX/SSZ/HCQ
RA 115 Rheumatoid Negative MTX/SSZ/HCQ
RA 143 Rheumatoid Negative MTX/SSZ/HCQ
RA 103 Rheumatoid Positive MTX/HCQ
RA 113 Rheumatoid Positive MTX
RA 128 Rheumatoid Positive MTX/SSZ/HCQ
RA 116 Rheumatoid Negative MTX/SSZ/HCQ
RA 144 Rheumatoid Negative MTX/SSZ/HCQ
RA 112 Rheumatoid Positive MTX
RA 107 Rheumatoid Negative MTX
BRH1095340 Ankylosing
spondyliztis
NA MTX
BRH1095341 Ankylosing
spondylitis
NA MTX
BRH1095342 Ankylosing
spondylitis
NA Enbrel/Indocin
BRH1095343 Ankylosing
spondylitis
NA MTX/Enbrel
BRH1095350 Psoriatic arthritis NA SSZ
BRH1095351 Psoriatic arthritis NA Dovonex
BRH1095903 Healthy control NA -
BRH1095904 Healthy control NA -
BRH1095905 Healthy control NA -
BRH1095906 Healthy control NA -
RF, Rheumatoid Factor; CCP, Anti-cyclic citrullinated peptide; MTX, methotrexate; SSZ,
sulphasalazine; HCQ, hydroxychloroquine.
comprised an initial denaturation step performed at 98◦C for
2min, followed by seven cycles of denaturation (98◦C, 10 s),
and annealing/extension (72◦C, 20 s) extension (72◦C, 15 s). A
final elongation of 5min at 72◦C completed the reaction. PCR
products were purified utilizing AMPure XP magnetic beads
(Agencourt) at a ratio of 0.8 beads to sample (v/v), eluted in 20
µl of UV-irradiated nuclease-free water and quantified utilizing
the Qubit 3.0 high-sensitivity DNA kit (Invitrogen).
Amplicons were barcoded using the Nextera DNA library
kit, multiplexed for efficiency and sequenced using the Ilumina
MiSeq system with a 250 bp paired-end read metric. All
samples underwent library preparation at the same time and
were sequenced on the same sequencer run. Three negative
control reactions, subjected to all experimental procedures, were
included on the sequencer run. Bioinformatic analysis was
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TABLE 2 | Oligonucleotide primers used in this study.
Primer
name
Primer sequence (5′–3′) Length
16SV4_F GTGCCAGCMGCCGCGGTAA 19
16SV4_R GGACTACHVGGGTWTCTAAT 20
16SV4_XT_F TCGTCGGCAGCGTCAGATGTGTATAAGAG
ACAGGTGCCAGCMGCCGCGGTAA
52
16SV4_XT_R GTCTCGTGGGCTCGGAGATGTGTATAAGAG
ACAGGGACTACHVGGGTWTCTAAT
54
performed using QIIME implemented as part of the Nephele
16S paired-end QIIME pipeline using open reference clustering
against the SILVA database for bacteria at a sequence identity of
99%. All other parameters remained as default.
The statistical significance of differences in the abundance
of individual bacteria among the RA, AS, PA, and control
donors was determined by the Kruskal Wallis test. In order
to detect differentially abundant bacterial species between pre-
and post-treatment RA patients (RA V0 and RA V3), a paired
Wilcoxon Signed-Rank test was applied. In all cases, P ≤
0.05 was considered statistically significant following multiple
testing correction.
RESULTS
16S rRNA PCR Amplification
Blood samples were obtained from 32 human subjects in total, as
described in Table 1. Among these, 20 were from patients with
clinician diagnosed RA who provided serum samples on their
first visit (V0) and at their 3-months review (V3). In addition,
samples from four patients with AS, four patients with PA, and
four healthy control subjects were investigated. Of the 20 patients
with RA, 11 were negative for Rheumatoid factor (RF) and/or
Anti-cyclic citrullinated peptide (CCP) negative while nine were
positive for RF/CCF. All patients with AS and PA recruited for
the study were receiving treatment for their respective condition.
Bacterial 16S rRNA amplification provided a total of 17
paired RA samples for analysis. Bacterial 16S rRNA amplification
was successful in 100% (4/4) AS, 50% (2/4) PA patients, and
100% (4/4) healthy donors providing a further 10 samples
for comparison. Our numerous experimental controls (free
template/kit controls) failed to generate a visible band following
PCR amplification and gel electrophoresis. Absence of amplified
products was subsequently confirmed by analysis with the
QuBit high-sensitivity DNA analysis system (ThermoFisher). As
a further precaution, we reviewed additional negative control
reactions that were sequenced on the same sequencing run
and at the same time as the samples reported herein. One
such sample generated mappable sequencing data (sample
NEGF) and comprised a small number of reads mapping to
Halomonas (6 reads), Corynebacterium 1 (64), Staphylococcus
(24), Ralstonia (1,726), Stenotrophomonas (460), Pseudomonas
(276), Escherichia-Shigella (2,420), and Ruminococcus (405) but
was overwhelmingly composed of reads mapping to the genus
Serratia (18,000). In order to control for this potential source
of contamination, we highlight any taxa that were found within
sample NEGF at a level >25% of the mean experimental sample
level i.e., on average, we require a potential contaminant to be
observed at a level greater or equal to four times that observed
in the negative control to consider its presence as convincing.
Application of this approach identified Serratia, Escherichia-
Shigella, Ralstonia, and Ruminococcus as potential contaminants,
and discussion of these taxa will make reference to this fact.
Characterization of the Circulating
Bacterial Community via 16S rRNA
Sequencing
The existence and characterization of microbial DNA in the
serumwere assessed by way of PCR amplification and sequencing
of the bacterial 16S rRNA gene (variable region 4) followed by
bioinformatic analysis using QIIME (seeMethods). Our primary
approach used principal coordinates analysis (PCoA) to reduce
the complexity of the data obtained and to immediately visualize
any obvious clustering among samples of different treatment
types (Figures 1A–C). Following ordination, it was immediately
obvious that the samples from our RA cohort clustered separately
to those from the PA, AS, and control patient samples. Indeed,
the RA samples clusteredmarkedly further away from the control
samples than did the PA or AS samples. These data suggest that
the bacterial community composition detected in the blood of
our RA patients was moremarkedly different from that of control
(Figure 1A) than were the bloodmicrobiome communities of the
PA or AS patient samples.
Principal Coordinate 1 accounted for >50% of the total
variance in the dataset, and samples appeared to cluster along
this axis (X) with control samples clustering toward the right, and
RA samples clustering toward the left. Given the paired nature of
our RA cohort, we linked pre- and post-treatment measurements
within in each patient (V0 and V3 shown in pink and blue,
respectively) by means of a black connecting line. For 13/17
sample pairs, the microbiome community appeared to progress
along Principal Coordinate 1 following treatment, suggesting
that the blood microbiome community in these samples became
more similar to that of the healthy control/ PA/AS population
following treatment.
In order to explore this effect in more detail, we considered
the above ordination in light of treatment type (Figure 1B)
and RF/CCP status (Figure 1C). Of the 17 RA patients for
which complete paired information was available (a successful
microbiome analysis pre- and post-treatment initiation), six
patients were prescribed methotrexate monotherapy (MTX), two
patients methotrexate plus hydroxychloroquine (MTX_HCQ),
one patient methotrexate plus sulphasalazine (MTX_SSZ), and
eight patients received a combination of all three drugs
(MTX_HCQ_SSZ). The 13 sample pairs that progressed toward
the right along PC1 post treatment came from patients
treated with a range of drug combinations (MTX, MTX_HCQ,
MTX_HCQ_SSZ, and MTX_SSZ). Furthermore, the four patient
samples that did not progress in this direction also came from
patients treated with a range of approaches (MTX, MTX_HCQ,
MTX_HCQ_SSZ, and MTX_SSZ), suggesting that the observed
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FIGURE 1 | PCoA plot informed by weighted unifrac distance matrix for RA V0 (pink), RA V3 (blue), AS (aqua), PA (mustard), and control subjects (green). Distance
matrix informed by amplification and sequencing of the 16S rRNA variable region four followed by taxonomic assignment. Where applicable, paired samples (V0, V3)
are linked by means of a black line. Proportions of variation explained by principal coordinates one and two are designated on the relevant axes. Variation explained by
the PCoA axes of ordination was 53.3% (PC1) and 15.22 % (PC2). (A) Samples are labeled by unique sample ID. (B) Samples are labeled by treatment type.
(C) Samples are labeled by RF/CCP status. RF, Rheumatoid Factor; CCP, Anti-cyclic citrullinated peptide.
shift in microbiome community membership was not influenced
by treatment modality. Conversely, of the 13 patients that
progressed toward the right along PC1 post treatment, 10
(77%) patients were RF/CCP negative and just three patients
RF/CCP positive. In contrast, three out of the four (75%)
patients that did not progress towards the right post treatment
were RF/CCP positive. These data suggest a role for RF/CCP
status in modulating the microbiome response following the
commencement of treatment with those patients with RF/CCP
negative RA more likely to progress toward a control/PS/PA
microbiome community than those who are RF/CCP positive.
Microbiome Community Composition
At the phylum level, the circulating microbiome of our study
samples was relatively consistent between the different patient
groups and predominated by Proteobacteria (45.8% of all
bacterial DNA) followed by Firmicutes (31.40%), Bacteroidetes
(10.9%), and Actinobacteria (10.20%). At the genus level
(Figure 2 and Supplementary Data 1), differences between
the various patient groups were evident. Control blood
samples were predominated by the genera Corynebacterium 1
(26.3%), Serratia∗ (17.10%), Streptococcus (9.1%), Pseudomonas
(7.3%), Anaerococcus (5.0%), Staphylococcus (4.3%), and
Achromobacter (4.0%). Blood samples from our AS patients
contained the same core genera and were predominated by
Serratia∗ (21.6%), Corynebacterium 1 (21.5%), Achromobacter
(7.8%), Pseudomonas (7.5%), Anaerococcus (5.0%), Streptococcus
(4.7%), and Staphylococcus (3.3%). Blood samples from
our two PA patients were similar and comprised Serratia∗
(19.5, 22.60%), Streptococcus (22.3, 8.0%), Corynebacterium 1
(14.3, 14.0%), Pseudomonas (7.2, 10.1%), Anaerococcus (6.4,
3.3%), Achromobacter (2.8, 8.1%), and Staphylococcus (3.1,
4.9%). In contrast, our RA samples were more distinct and
predominated by Halomonas (21.7, 19.5% for V0 and V3,
respectively), Anaerococcus (8.0, 6.8%), Pseudomonas (7.3,
8.4%), Corynebacterium 1 (5.7, 6.6%), Shewanella (6.5, 5.7%),
and members of the Lachnospiraceae NK4A136 group (4.8,
5.5%). ∗Potential contaminant present within a single negative
control reaction at a level exceeding that observed in our
experimental samples.
Statistical analysis of those genera representing at least 1% of
any one experimental group was conducted using the Kruskal
Wallis test. Nineteen genera were significantly altered by disease
status and are detailed inTable 3. Post hoc analysis was performed
using the Dunn Test with Benjamini-Hochberg correction for
multiple comparisons. At presentation, and prior to treatment
(V0), rheumatoid arthritis was associated with significantly
elevated levels of Halomonas and Shewanella and significantly
decreased levels of Achromobacter, Escherichia-Shigella∗,
Serratia∗, Corynebacterium 1, Streptococcus, Granulicatella,
Gemella, and Staphylococcus relative to our healthy control
subjects (Figure 3). Comparison of the means of V0 and
V3 revealed no significant changes in these specific genera
when the patients provided a further blood sample following
3-months of treatment (V3). Interestingly, differences in the
circulating microbiome composition between our healthy
control donors and those patients with AS or PA were not
statistically significant.
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FIGURE 2 | Relative abundance of genera detected within the blood. Data are the relative abundance of the major bacterial taxa, characterized as having a mean
abundance of >1% of the total bacteria content in any one experimental group, identified in the serum of rheumatoid arthritis (RA V0, n = 18, and RA V3, n = 18 or
which n = 17 are paired), ankylosing spondylitis (AS, n = 4), psoriatic arthritis (PA, n = 2), and control (Control, n = 4) samples as determined using amplification and
sequencing of the 16S rRNA gene variable region 4. Data are mean abundance expressed as a percentage of the total bacterial sequence count.
In order to further explore the results of our ordination
which suggested that the circulating microbiome of many of
our RA patients moved closer toward the healthy control state
post treatment, we analyzed the V0 and V3 data for all taxa
taking into account the paired nature of these observations.
Wilcoxon Signed-Rank Test analysis revealed that members
of the genera Haemophilus, Alloprevotella, Eremococcus, and
Lachnospiraceae_UCG001 were significantly altered between V0
and V3 (Figure 4).
DISCUSSION
There is emerging evidence to support the hypothesis that pan-
microbiome dysbiosis in the gut and other locations of patients
with RA, AS, and PA is associated with the pathogenesis of
disease or disease status (Gilis et al., 2018). However, changes in
the blood microbiome of patients with RA, AS, and PA remain
understudied. The presence of microbial DNA, either within
bacterial cells or in free-form, creating a circulating microbiome
is a topic that is being still debated by some (Castillo et al., 2019).
However, recent studies have provided evidence for the existence
of circulating microbial DNA using a range of different methods
(Whittle et al., 2019). While skepticism remains about the origin
of the bacterial DNA found in these studies (Hornung et al.,
2019), we remain confident in the existence of such given the
continued observation that such communities differ by disease
state, even when samples are completely randomized prior to and
during processing.
Our analyses revealed the presence of a complex serum
microbiome community in health and disease. At the phylum
level, the bloodmicrobiome was predominated by key four phyla;
Proteobacteria, Firmicutes, Bacteroidetes, andActinobacteria, and
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TABLE 3 | Genera significantly altered by disease status.
Taxonomy Kruskal Wallis P-Value PA FDR P-value AS FDR P-value RA V0 FDR P-value RA V3 FDR P-Value
D_5__Halomonas 0.000 ns ns 0.006 0.02
D_5__Shewanella 0.000 ns ns 0.009 0.01
D_5__Achromobacter 0.000 ns ns 0.010 0.008
D_5__Escherichia-Shigella* 0.000 ns ns 0.007 0.005
D_5__Serratia* 0.000 ns ns 0.009 0.01
D_5__Corynebacterium 1 0.000 ns ns 0.004 0.007
D_5__Streptococcus 0.001 ns ns 0.007 0.01
D_5__Granulicatella 0.003 ns ns 0.03 0.02
D_5__Gemella 0.004 ns ns 0.01 0.05
D_5__Lachnospiraceae NK4A136 group 0.005 ns ns 0.07 0.05
D_5__Staphylococcus 0.005 ns ns 0.03 ns
D_5__Chryseobacterium 0.005 ns ns ns ns
D_5__Acinetobacter 0.010 ns ns ns ns
D_5__Ruminococcaceae UCG-014 0.010 ns ns ns ns
D_5__Neisseria 0.013 ns ns ns ns
D_5__Turicella 0.018 ns ns ns ns
D_5__Alistipes 0.035 ns ns ns ns
D_5__Methylobacterium 0.043 ns ns ns ns
D_5__Bacteroides 0.044 ns ns ns ns
*Taxa previously associated with contamination and identified within a single negative control reaction run at the same time as the samples reported herein. ns, not statistically significant.
these data further support the notion of a core blood microbiome
(Amar et al., 2013; Lelouvier et al., 2016; Païssé et al., 2016; Olde
Loohuis et al., 2018; Whittle et al., 2018). Many of the genera
identified in this study have previously been identified by us in
the blood of healthy human donors as part of a separate study,
albeit in differing proportions (Whittle et al., 2019), and by others
among both healthy and diseased individuals (Damgaard et al.,
2015; Lelouvier et al., 2016; Païssé et al., 2016; Santiago et al.,
2016; Li et al., 2018; Qiu et al., 2019).
Microbiome Composition and Disease
Comparison of the serum microbiome of the 17 paired patient
samples with RA, four patients with AS, two patients with PA,
and the four healthy controls through PCoA revealed that the
composition of microbiome of the RA cohort was different from
that of AS, PA cohorts, and the healthy controls, the latter three
groups being more similar in their composition. AS and PA both
belong to the group of conditions termed spondyloarthritides
and share more similarities in their pathogenesis than does
RA (Lories and Baeten, 2009), supporting their close proximity
in PcOA space. All patients with AS and PA recruited for
the present study were receiving treatment, though details of
their disease activity at the time of donation were unknown.
Therefore, either a lack of active disease or a difference in the
pathogenesis may be the reasons for the similarity of serum
microbiomes among the healthy controls and patients with AS
and PA.
Our PcOA analysis identified key differences between
the serum microbiome of our patients with RA compared
to those with AS, PA, and our healthy control subjects
demonstrated by the fact that these samples occupied a
distinct location in the PcOA space. The genera Halomonas,
Anaerococcus, Pseudomonas, Corynebacterium, Shewanella, and
Lachnospiraceae NK4A136_group were most abundant in the
RA serum. Many of these have also been identified in the
human blood microbiome previously with the exception of
Halomonas species, which accounted for the majority of reads
at genus level (Damgaard et al., 2015; Lelouvier et al., 2016;
Païssé et al., 2016; Santiago et al., 2016; Li et al., 2018; Qiu et al.,
2019).
Following statistical analysis, a number of taxa were found to
significantly differ in their abundance between the RA patients
and the other three patient groups.
Halomonas and Shewanella were found to be significantly
higher among our RA patients in comparison to PA, AS, or
healthy control subjects. Halomonas species are a group of
halophilic and halotolerant bacteria that have been recently
implicated in a limited number of human infections including
dialysis associated sepsis (Kim et al., 2013). Halomonas species
have been identified in the skin microbiome of humans (Grice
et al., 2008). Evidence of this genus has also been found in
a salt tolerance locus of the human gut microbiome (Culligan
et al., 2013) and identified at elevated levels in the gut mucosal
microbiome of patients with rectal cancers along with Shewanella
species. Identification of Halomonas in the salivary microbiome
has been associated with inflammatory markers such as IL-
1β (Acharya et al., 2017), key inflammatory cytokines also
associated with RA. However, Halomonas has been identified
as a possible contaminant due to its presence in negative
control samples subjected to sequencing (Santiago et al., 2016;
Whittle et al., 2019). That said, only six reads mapping to
the genus Halomonas were identified in the single negative
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FIGURE 3 | Relative abundance of significantly altered genera detected in the serum of rheumatoid arthritis (RA V0 and RA V3), AS, and PA relative to healthy control
serum. Data determined through the amplification and sequencing of the 16S rRNA gene. Data are mean abundance expressed as a percentage of the total bacterial
sequence count and scaled between 0 and 1.
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FIGURE 4 | Relative abundance of those taxa identified as being treatment-responsive (A) Haemophilus, (B) Alloprevotella, (C) Eremococcus, (D)
Lachnospiraceae_UGC-001. Data are mean abundance expressed as a percentage of the total bacterial sequence count and scaled between 0 and 1. Black lines link
paired observations.
control returning sequence data relative to a mean of 3,500 reads
identified in our experimental samples.
Shewanella species have been increasingly associated with
human infections (Yousfi et al., 2017). Shewanella species have
been found to be perturbed in the human gut microbiome
in different physiological and disease conditions (Rojo et al.,
2017; Smid et al., 2018), and Shewanella has been identified
in the blood microbiome of healthy people, particularly
associated with RBCs (Païssé et al., 2016). Of interest is
the fact that both genera found to be increased in patients
with RA are salt tolerant. Liao et al. have identified both
Shewanella and Halomonas along with other bacteria to be
increased in the gut microbiome of mice fed with chondroitin
sulfate. This has been associated with gut inflammation as
well as joint inflammation, leading to the hypothesis that
the change in the gut microbiome contributes to the pro-
inflammatory state (Liao et al., 2017). Despite other studies
identifying this genus as a potential contaminant, we found
no evidence of such in our negative control reactions. As
a number of studies have identified these two genera to
co-exist, our findings cannot be disregarded as incidental
or contaminants. Animal studies or cell line studies with
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co-inoculation of these genera would help to explore this
lead further.
Achromobacter, Escherichia/Shigella∗, Serratia∗,
Corynebacterium-1, Streptococcus,Granulicatella, Staphylococcus,
and Gemella were the genera significantly reduced in abundance
in our RA cohort. Of these, Achromobacter and to a lesser
extent Serratia∗ have been identified as lymphoid tissue resident
commensal (LRC) bacteria in humans and animals. A healthy
community of LRC bacteria regulate their own growth through
IL-22 to regulate systemic inflammation (Fung et al., 2016).
Therefore, a reduction in these bacterial DNA in the serum
of patients with RA may indicate a pro-inflammatory state.
Gemella and Granulicatella were also found to be reduced in
the sub gingival microbiome of patients with RA (Lopez-Oliva
et al., 2018), confirming their existence in classical microbiome
niches. Members of the genera Streptococci, Staphylococci, and
Corynebacterium are part of the normal microbiome of the skin,
oral cavity, as well as the gut. Therefore, their reduction, as we
have noted in the serum microbiome of our patients, along with
the other changes noted above, hints toward dysbiosis at these
distant sites, reflected in the abundance of DNA reaching the
circulatory system.
Effect of Treatment on the Microbiome
A key finding in our study was that the serum microbiome
of 13/17 patients with RA progressed along PC1 following
the instigation of treatment toward the healthy control/PA/AS
samples. Existing evidence reports that the microbiome of
different sites does partially normalize with treatment in patients
with rheumatoid arthritis (Zhang et al., 2015); however, these
findings have not been uniform (Beyer et al., 2018; Mikuls
et al., 2018), perhaps due to the different study designs,
sampling sites, or the technologies used. While the effect in
our present study was not associated with any one specific
treatment modality, 3/4 of the patients with a “non-responsive
serum microbiome” had seropositive rheumatoid arthritis, while
the majority (77%) of those who responded were seronegative.
Clearly, further exploration is warranted here. Previous studies
have demonstrated a change in the oral and gut microbiome
in patients with RA when treated with MTX and Etanercept
(Zhang et al., 2015; Picchianti-Diamanti et al., 2018). While
many studies do not differentiate between treatment response
and seropositivity, a recent study has further demonstrated that
seronegative rheumatoid arthritis may show a better response to
treatment (Choi and Lee, 2018). In our study, there was a better
normalization of the serum microbiome among the seronegative
arthritis group, in line with previously published findings. A
recent review illustrates the importance of the gut microbiome in
drug metabolism, and growing evidence suggests that differences
in the gut microbiome community may explain individual drug
responses (Zimmermann et al., 2019).
Abundance of the genera Haemophilus, Alloprevotella,
Eremococcus, and Lachnospiraceae_UGC-001 increased
significantly with treatment and contributed to the normalization
of the microbiome. Haemophilus species have been recognized
to be depleted in the gut and oral microbiomes of patients with
RA (Zhang et al., 2015; Wu et al., 2016), and our blood-based
characterization supports this. Lachnospiraceae_UGC-001 was
found to be increased with disease and further elevated following
treatment. Previous human as well as animal studies have further
found these taxa to be increased in individuals with RA (Liu et al.,
2016; Wu et al., 2016). Alloprevotella species were previously
found to be increased in the oral microbiome of patients with
RA irrespective of the status of periodontal hygiene (Wolff et al.,
2017), whereas we found this genus to be decreased in RA relative
to the healthy state. No studies consider Eremococcus in relation
to RA to date. While our findings were not in full agreement
with enriched/depleted taxa found at different body sites in RA
in previous studies, one must remember that our analyses are
conducted in the blood which likely receives microbial DNA
from a range of niches. On this basis, these results certainly
warrant further investigation.
Limitations
It is noteworthy here that all samples were processed in parallel
and in a randomized order to avoid the introduction of batch
effects. In exploring the fact that our RA cohort clustered entirely
separately from the other samples in our PcOA analysis, it is
imperative to highlight here that while we closely controlled all
analytical parameters from the moment of sample acquisition,
our sample cohorts were procured from different sources,
arriving as blood product samples in sterile plasticware. It is
possible therefore that some differences in their microbiome
composition could be explained by variables for which data were
not available for our procured material, differences in collection
technique or even the immediate environment at the time of
collection. We are aware that the microbiome is modulated by
a range of factors, and such analyses are highly sensitive to pre-
analytical conditions.While we were unable to practically address
this limitation herein given the retrospective nature of our study
design, we advocate strongly for further prospective studies in
this area, which control pre-analytical conditions inclusive of the
sample collection phase.
CONCLUDING REMARKS
Through amplification and sequencing of the bacterial 16S rRNA
gene, we describe the existence of a blood microbiome in health
and in disease. We identify specific taxa that appear to correlate
with disease and a further distinct set of taxa that appear to
correlate with treatment response. Community level analysis
(informed by PcOA) demonstrates that the microbiome of our
RA patients appeared to change following treatment. In the
main, the taxa identified as disease or treatment responsive
have been previously described as common inhabitants of
the human microbiome, more commonly found in the oral
cavity and gut. These data support our developing hypothesis
that microbial DNA found within the blood translocates from
more classical microbiome niches that are undergoing disease-
association perturbation and therefore, has the potential to
serve as a novel biomarker in RA pathogenesis and treatment
response. Further studies are required to investigate these
preliminary findings.
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